Therapeutic Asset Ratings

309 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
qlf31907 Melanoma	Qilu Pharmaceutical Co., Ltd.	P2	CCC (48)
Rain-32 Melanoma	Rain Oncology Inc	P2	CCC (48)
Rosiglitazone Melanoma	Dan Zandberg	P2	CCC (48)
Sarilumab Melanoma	NYU Langone Health	P2	CCC (48)
Shr-1701 Melanoma	Shanghai Zhongshan Hospital	P2	CCC (48)
Tak-228 Melanoma	National Cancer Institute (NCI)	P2	CCC (48)
Tas-102 Melanoma	National Cancer Institute (NCI)	P2	CCC (48)
tqb2916 Melanoma	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	P2	CCC (48)
vv1 Melanoma	Vyriad, Inc.	P2	CCC (48)
BMS 986253 Melanoma	Yana Najjar	P1/2	CCC (48)
CDX 1140 Melanoma	University of Southern California	P1/2	CCC (48)
Taselisib Melanoma	National Cancer Institute (NCI)	P2	CC (47)
Copanlisib Melanoma	National Cancer Institute (NCI)	P2	CC (46)
Sitravatinib Melanoma	Peking University Cancer Hospital & Institute	P2	CC (46)
Acetazolamide Melanoma	Obsidian Therapeutics, Inc.	P1/2	CC (46)
Obinutuzumab Melanoma	Simcha IL-18, Inc.	P1/2	CC (46)
Obx-115 Melanoma	Obsidian Therapeutics, Inc.	P1/2	CC (46)
Recombinant Human Interferon Α1B Melanoma	Xijing Hospital	P1/2	CC (46)
Trk-950 Melanoma	Toray Industries, Inc	P1/2	CC (46)
n-803 Melanoma	ImmunityBio, Inc.	P2	CC (45)
Tigilanol Tiglate Melanoma	QBiotics Group Limited	P2	CC (44)
Tovorafenib Melanoma	Day One Biopharmaceuticals, Inc.	P2	CC (44)
Cetuximab Melanoma	C4 Therapeutics, Inc.	P1	CC (44)
e-602 Melanoma	Palleon Pharmaceuticals, Inc.	P1/2	CC (44)
e7386 Melanoma	Eisai Inc.	P1/2	CC (44)

Showing 126 to 150 of 309 assets